{
  "ticker": "CMP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968945",
  "id": "02968945",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrx63l14q6jy.pdf",
  "summary": "- **Record sales orders**: $63.4 million, up 22% YoY, led by Sleep & Neurology (+39%) and SaaS (+49%).  \n- **US growth**: Sales orders up 115% YoY; SaaS (Somfit) orders surged 675% to $3.1 million.  \n- **Revenue (unaudited)**: $51.0 million (+4% YoY), with Sleep & Neurology up 16% and SaaS up 41%.  \n- **EBITDA**: ~$3 million (return to profitability); margin uplift from SaaS scaling and cost control.  \n- **FY26 guidance**: Revenue \u2265$70 million, EBITDA ~$9 million; SaaS to contribute >20% of revenue.  \n- **Growth drivers**: US launch of disposable Somfit (targeting $150M\u2013$300M market), 3 MEG systems (~$15M revenue in FY26).  \n- **Capital raise**: $4.1 million for working capital.  \n\n*Omitted: Operational details, director commentary, historical segment breakdowns.*",
  "usage": {
    "prompt_tokens": 1888,
    "completion_tokens": 221,
    "total_tokens": 2109,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:44:41.128540"
}